Alnylam, Medtronic highlight RNAi drug-device combo data

Alnylam Pharmaceuticals ($ALNY) and Medtronic ($MDT), with the support of the nonprofit CHDI Foundation, are evaluating their RNAi drug-device combination to treat Huntington's disease. They point to promising preclinical results suggesting that their test led to "significant silencing" of the huntingtin gene in the striatum and surrounding brain tissue. Details are published in the journal Experimental Neurology. Report

Suggested Articles

Medtronic has moved to acquire Avenu Medical, developers of a minimally invasive method of building the blood vessel access ports.

The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.

Smith & Nephew has signed up to acquire Integra LifeSciences’ orthopedics business focused on the growing upper and lower extremity markets.